CY1123583T1 - Ανοσογονος συνθεση για χρηση στη θεραπεια - Google Patents

Ανοσογονος συνθεση για χρηση στη θεραπεια

Info

Publication number
CY1123583T1
CY1123583T1 CY20201101066T CY201101066T CY1123583T1 CY 1123583 T1 CY1123583 T1 CY 1123583T1 CY 20201101066 T CY20201101066 T CY 20201101066T CY 201101066 T CY201101066 T CY 201101066T CY 1123583 T1 CY1123583 T1 CY 1123583T1
Authority
CY
Cyprus
Prior art keywords
type
capsular saccharide
therapy
gilding
conjugate
Prior art date
Application number
CY20201101066T
Other languages
English (en)
Inventor
Ralph Leon Biemans
Dominique Boutriau
Philippe Denoel
Pierre Duvivier
Carine Goraj
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1123583T1 publication Critical patent/CY1123583T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η αίτηση διπλώματος ευρεσιτεχνίας αποκαλύπτει μια μέθοδο ανοσοποίησης εναντίον της λοίμωξης από τον χρυσίζωντα Σταφυλόκοκκο, η οποία περιλαμβάνει ένα βήμα χορήγησης σε έναν άνθρωπο ασθενή μιας μοναδιαίας δόσης μιας ανοσογόνου σύνθεσης, η οποία περιλαμβάνει έναν Τύπου 5 καψικό σακχαρίτη χρυσίζωντος Σταφυλόκοκκου συζευγμένο σε μια πρωτεΐνη φορέα ώστε να σχηματιστεί ένα σύζευγμα Τύπου 5 καψικού σακχαρίτη χρυσίζωντος Στ., όπου το σύζευγμα Τύπου 5 καψικού σακχαρίτη χρυσίζωντος Στ. χορηγείται σε μια δόση σακχαρίτη 3-50μg.
CY20201101066T 2013-06-05 2020-11-11 Ανοσογονος συνθεση για χρηση στη θεραπεια CY1123583T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1310008.6A GB201310008D0 (en) 2013-06-05 2013-06-05 Immunogenic composition for use in therapy
PCT/EP2014/061424 WO2014195280A1 (en) 2013-06-05 2014-06-03 Immunogenic composition for use in therapy

Publications (1)

Publication Number Publication Date
CY1123583T1 true CY1123583T1 (el) 2022-03-24

Family

ID=48805771

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101066T CY1123583T1 (el) 2013-06-05 2020-11-11 Ανοσογονος συνθεση για χρηση στη θεραπεια

Country Status (24)

Country Link
US (3) US20160129101A1 (el)
EP (1) EP3003363B1 (el)
JP (2) JP2016524619A (el)
KR (1) KR102266346B1 (el)
CN (1) CN105517567A (el)
AU (1) AU2014277027B2 (el)
BE (1) BE1021938B1 (el)
BR (1) BR112015029931B1 (el)
CA (1) CA2912496C (el)
CY (1) CY1123583T1 (el)
DK (1) DK3003363T3 (el)
EA (1) EA033488B1 (el)
ES (1) ES2830785T3 (el)
GB (1) GB201310008D0 (el)
HR (1) HRP20201683T1 (el)
HU (1) HUE051358T2 (el)
IL (1) IL242584B (el)
LT (1) LT3003363T (el)
MX (1) MX2015016750A (el)
PL (1) PL3003363T3 (el)
PT (1) PT3003363T (el)
SG (1) SG11201509406QA (el)
SI (1) SI3003363T1 (el)
WO (1) WO2014195280A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101408113B1 (ko) * 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
JP5914344B2 (ja) * 2009-10-30 2016-05-11 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ５型および８型の莢膜糖の精製
EP3229833A1 (en) * 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Method of treatment
WO2017079681A1 (en) * 2015-11-05 2017-05-11 The Texas A&M University System Targeting of ligand binding sites in clfa
RU2689161C1 (ru) * 2018-10-04 2019-05-24 Федеральное бюджетное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения бактериальных антигенов

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
HU219056B (hu) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO2000012132A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
EP1121135B1 (en) 1998-09-14 2009-01-28 Nabi Biopharmaceuticals Compositions of beta-glucans and specific immunoglobulins
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
AU2004220590B2 (en) 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
EP1644734B1 (en) 2003-07-09 2011-11-23 Life Technologies Corporation Method for assaying protein-protein interaction
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP5174457B2 (ja) 2004-05-11 2013-04-03 デ スタート デール ネーダーランデン， フェルテヘンウォールディヒィト ドール デ ミニステール ファン フォルクスヘーゾンドハイド， フェルザイン アン スポルト アジュバントとしての髄膜炎菌ｌｇｔＢＬＯＳ
EP2476434A1 (en) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
NZ574057A (en) * 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen
MX2010008423A (es) 2008-01-31 2010-09-22 Trinity College Dublin Tratamiento de infecciones microbianas.
JP2012530785A (ja) 2009-06-22 2012-12-06 ワイス・エルエルシー 組成物および黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）血清型５および８莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
JP5914344B2 (ja) 2009-10-30 2016-05-11 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ５型および８型の莢膜糖の精製
AU2011274367B2 (en) * 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
DK3150222T3 (da) 2010-12-22 2020-01-27 Wyeth Llc Stabile immunogene sammensætninger af staphylococcus aureus-antigener

Also Published As

Publication number Publication date
BR112015029931B1 (pt) 2021-01-12
EA201592040A1 (ru) 2016-06-30
GB201310008D0 (en) 2013-07-17
JP2016524619A (ja) 2016-08-18
LT3003363T (lt) 2020-12-28
CA2912496A1 (en) 2014-12-11
SG11201509406QA (en) 2015-12-30
US20170056490A1 (en) 2017-03-02
JP2019123720A (ja) 2019-07-25
AU2014277027A1 (en) 2015-12-24
ES2830785T3 (es) 2021-06-04
IL242584B (en) 2021-06-30
EA033488B1 (ru) 2019-10-31
US20160129101A1 (en) 2016-05-12
MX2015016750A (es) 2016-04-13
EP3003363A1 (en) 2016-04-13
BE1021938B1 (fr) 2016-01-27
SI3003363T1 (sl) 2020-12-31
KR20160018604A (ko) 2016-02-17
CN105517567A (zh) 2016-04-20
KR102266346B1 (ko) 2021-06-17
WO2014195280A1 (en) 2014-12-11
EP3003363B1 (en) 2020-08-19
CA2912496C (en) 2023-01-17
PL3003363T3 (pl) 2021-04-06
HRP20201683T1 (hr) 2020-12-25
US20180104322A1 (en) 2018-04-19
DK3003363T3 (da) 2020-11-09
PT3003363T (pt) 2020-11-16
HUE051358T2 (hu) 2021-03-01
JP6773830B2 (ja) 2020-10-21
AU2014277027B2 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
CY1123583T1 (el) Ανοσογονος συνθεση για χρηση στη θεραπεια
CY1123688T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20
CY1122628T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
NI201700024A (es) Tratamientos médicos a base de anamorelina
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1123600T1 (el) Μεθοδος θεραπειας
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
RU2013153030A (ru) Способ введения лекарственного препарата на постоперационную рану при непосредственном зубном или челюстном протезировании
EA201791895A1 (ru) Дозы и способы введения телаванцина
CY1115322T1 (el) Εκχυλισμα τριγωνελλας για τη θεραπεια νοσων στον ανθρωπο και τα ζωα στις οποιες εμπλεκονται μαστιγομορφα παρασιτα
RU2012129115A (ru) Способ лечения острых послеродовых эндометритов у коров
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
NI201800105A (es) Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos.
PE20160186A1 (es) Composicion farmaceutica para tratamiento de la vasculopatia coroidea polipoidal
AR087811A1 (es) Vacuna contra el staphylococcus aureus
MX2017007652A (es) Metodo de tratamiento.